Equities

Charlotte's Web Holdings Inc

Charlotte's Web Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)0.20
  • Today's Change0.01 / 5.26%
  • Shares traded10.55k
  • 1 Year change-68.25%
  • Beta1.9147
Data delayed at least 15 minutes, as of Sep 20 2024 17:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Charlotte's Web Holdings Inc share price to rise to 0.5017 in the next year from the last price of 0.19.
High164.0%0.5017
Med164.0%0.5017
Low164.0%0.5017

Earnings history & estimates in USD

On Aug 08, 2024, Charlotte's Web Holdings Inc reported 2nd quarter 2024 losses of -0.07 per share. This result was in line with the expectation of the one analyst following the company and under-performed last year's 2nd quarter results by -0.09.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate+7.78%
Charlotte's Web Holdings Inc reported annual 2023 losses of -0.16 per share on Mar 21, 2024.
Average growth rate-44.05%
More ▼

Revenue history & estimates in USD

Charlotte's Web Holdings, Inc. had 2nd quarter 2024 revenues of 12.29m. This missed the 13.42m consensus estimate of the 2 analysts following the company. This was 27.71% below the prior year's 2nd quarter results.
Average growth rate-5.49%
Charlotte's Web Holdings, Inc. had revenues for the full year 2023 of 63.16m. This was 14.82% below the prior year's results.
Average growth rate-9.02%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.